The first stop for professional medicines advice

Supply

23 results

RelevanceNewest firstOldest firstTitle
Applied filters

Use of off-label or unlicensed products under Human Medicines Regulations 2012 Schedule 17 exemptions

8 January 2020The below summary details the legal position regarding the sale, supply or administration of off-label/unlicensed products under Schedule 17 of the HMR 2012

Patient Group Direction use in End of Life Care

10 August 2020Considerations required before implementing Patient Group Direction (PGDs) for in End of Life Care

Mixing of medicines and Patient Group Directions

9 September 2020This article provides advice on the legal considerations required when considering mixing medicines to be supplied or administered under a PGD

Patient Group Directions (PGDs) and abortifacients

14 September 2020This article advises on the legal position on the supply/administration of abortifacients under PGDs.

Inclusion of medicines with Risk Minimisation Measures (RMM) in Patient Group Directions

16 March 2021This article reflects MHRA guidance on the use of PGDs for medications which have risk minimisation measures (RMM).

Off label medicine use under a Patient Group Direction

10 June 2021This article explains the legislation and guidance on the use of PGDs when a medicine is to be used outside its licence ('off label')

Using a Patient Group Direction to adjust doses of medicines

16 November 2021This article outlines why PGDs cannot be used to adjust the dosage of a medicine already in an individual's possession

Unlicensed medicines and use of PGDs

16 November 2021This page explains why PGD are not legal mechanism for the administration or supply of unlicensed medicines.

Supply and/or administration of Controlled Drugs under a Patient Group Direction

16 November 2021This article summarises the legal position on the supply and/or administration of controlled drugs under PGDs.

Understanding transcribing for medicines administration in healthcare

22 February 2022Transcribing is accurately copying medication details. It requires assessment and mitigation against identified risks in different settings.